FDA extends PDUFA date for Alexza's Adasuve

FDA extended the PDUFA date by three months for an NDA from Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) for inhaled Adasuve Staccato loxapine to treat agitation in patients with schizophrenia or bipolar...